Paul Daruwala's most recent trade in Cidara Therapeutics Inc was a trade of 16,199 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on Sept. 12, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 12 Sep 2022 | 16,199 | 221,099 (0%) | 0% | 0.7 | 11,095 | Common Stock |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 50,000 | 237,298 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 132,000 | 182,531 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Paul Daruwala | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) |